Skip to main content

Table 4 Univariate and multivariate analyses of overall survival (N = 30)

From: Comparison of the clinical courses and chemotherapy outcomes in metastatic colorectal cancer patients with and without active Mycobacterium tuberculosis or Mycobacterium kansasiiinfection: a retrospective study

Variable   N MST P value/HR (95% CI)
    (Months) Univariate Multivariate
Sex     
  Male 20 29.4 0.458  
  Female 10 22.6 1.44 (0.54–3.81)  
Age     
  <69 14 29.4 0.569  
  ≥69 16 22.6 1.30 (0.53–3.16)  
Performance status     
  0–1 19 36.1 0.002 0.004
  2–4 11 11.4 4.06 (1.58–10.43) 4.11 (1.57–10.76)
CEA (ng/ml)     
  <16.9 14 29.4 0.386  
  ≥16.9 16 22.6 1.51 (0.59–0.82)  
K-ras     
  Wild-type 12 17.4 0.051  
  Mutated 14 36.7 0.357 (0.12–1.05)  
Stage     
  Relapse after surgery 15 36.7 0.453  
  IV 15 22.6 1.42 (0.56–3.59)  
Respiratory diseases     
  No 19 22.6 0.875  
  Yes 11 29.4 0.93 (0.37–2.34)  
MTB or MK infection   
  No 23 22.6 0.536  
  Yes 7 36.7 0.705 (0.23–2.15)  
Primary site     
  Rectum 16 29.4 0.322  
  Colon 14 22.6 0.615 (0.23–1.62)  
Number of metastatic organs     
  1 13 36.7 0.0893  
  ≥2 17 16.9 2.2 (0.87–5.58)  
Lung metastasis     
  No 12 16.9 0.483  
  Yes 18 29.4 0.72 (0.29–1.79)  
Liver metastasis     
  No 17 36.1 0.020 0.030
  Yes 13 11.9 3.24 (1.15–9.11) 3.37 (1.13–10.07)
  1. HR: hazard ratio, CI: confidence interval, MST: median survival time.
  2. CEA: carcinoembryonic antigen, MTB: Mycobacterium tuberculosis, MK: Mycobacterium kansasii.